middle.news
Dimerix CEO Details $1.9 Billion Kidney Pipeline and New Phase 2 Asset
8:17am on Thursday 6th of August, 2026 AEST
•
Healthcare
Read Story
Dimerix CEO Details $1.9 Billion Kidney Pipeline and New Phase 2 Asset
8:17am on Thursday 6th of August, 2026 AEST
Key Points
Five licensing partners with deals worth up to A$1.9 billion
DMX-200 Phase 3 trial for FSGS fully recruited and progressing
DMX-652 Phase 2-ready asset targeting acute kidney injury with FDA clearance
Multi-region strategy reduces risk and accelerates global market access
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE